The Effect of Growth Hormone on Bioactive IGF in Overweight/obese Women

Overview

Journal Growth Horm IGF Res

Publisher Elsevier

Specialty Endocrinology

Date 2018 Apr 22

PMID 29679919

Citations 3

Authors

Laura E Dichtel

Mette Bjerre

Melanie Schorr

Miriam A Bredella

Anu V Gerweck

Brian M Russell

Jan Frystyk

Karen K Miller

Affiliations

Soon will be listed here.

Abstract

Objective: Overweight/obesity is characterized by decreased growth hormone (GH) secretion whereas circulating IGF-I levels are less severely reduced. Yet, the activity of the circulating IGF-system appears to be normal in overweight/obese subjects, as estimated by the ability of serum to activate the IGF-I receptor in vitro (bioactive IGF). We hypothesized that preservation of bioactive IGF in overweight/obese women is regulated by an insulin-mediated suppression of IGF-binding protein-1 (IGFBP-1) and IGFBP-2, and by suppression of IGFBP-3, mediated by low GH. We additionally hypothesized that increases in bioactive IGF would drive changes in body composition with low-dose GH administration.

Design: Cross-sectional analysis and 3-month interim analysis of a 6-month randomized, placebo-controlled study of GH administration in 50 overweight/obese women without diabetes mellitus. Bioactive IGF (kinase receptor activation assay) and body composition (DXA) were measured.

Results: Prior to treatment, IGFBP-3 (r = -0.33, p = 0.02), but neither IGFBP-1 nor IGFBP-2, associated inversely with bioactive IGF. In multivariate analysis, lower IGFBP-3 correlated with lower peak stimulated GH (r = 0.45, p = 0.05) and higher insulin sensitivity (r = -0.74, p = 0.003). GH administration resulted in an increase in mean serum IGF-I concentrations (144 ± 56 to 269 ± 66 μg/L, p < 0.0001) and bioactive IGF (1.29 ± 0.39 to 2.60 ± 1.12 μg/L, p < 0.0001). The treatment-related increase in bioactive IGF, but not total IGF-I concentration, predicted an increase in lean mass (r = 0.31, p = 0.03) and decrease in total adipose tissue/BMI (r = -0.43, p = 0.003).

Conclusions: Our data suggest that in overweight/obesity, insulin sensitivity and GH have opposing effects on IGF bioactivity through effects on IGFBP-3. Furthermore, increases in bioactive IGF, rather than IGF-I concentration, predicted GH administration-related body composition changes.

Clinical Trial Registration Number: NCT00131378.

Citing Articles

Reduced Growth Hormone Predicts Worsening Adipose Tissue Insulin Resistance in Adults with Obesity.

Li X, Zhou B, Yao Y, Wang G, Meng H Obes Facts. 2023; 16(4):401-410.

PMID: 37231915 PMC: 10427958. DOI: 10.1159/000530734.

Impact of BMI on peak growth hormone responses to provocative tests and therapeutic outcome in children with growth hormone deficiency.

Yang A, Cho S, Kwak M, Kim S, Park S, Jin D Sci Rep. 2019; 9(1):16181.

PMID: 31700044 PMC: 6838176. DOI: 10.1038/s41598-019-52644-1.

Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome.

Devin J, Nian H, Celedonio J, Wright P, Brown N J Clin Endocrinol Metab. 2019; 105(1).

PMID: 31529097 PMC: 7947776. DOI: 10.1210/clinem/dgz028.

References

Maccario M, Ramunni J, Oleandri S, Procopio M, Grottoli S, Rossetto R . Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. Int J Obes Relat Metab Disord. 1999; 23(6):612-8. DOI: 10.1038/sj.ijo.0800889. View

Sadick M . Kinase Receptor Activation (KIRA): a rapid and accurate alternative to endpoint bioassays. Dev Biol Stand. 1999; 97:121-33. View

Matsuda M, DeFronzo R . Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999; 22(9):1462-70. DOI: 10.2337/diacare.22.9.1462. View

Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H . Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev. 1999; 15(5):314-22. DOI: 10.1002/(sici)1520-7560(199909/10)15:5<314::aid-dmrr56>3.0.co;2-e. View

Maccario M, Tassone F, Gauna C, Oleandri S, Aimaretti G, Procopio M . Effects of short-term administration of low-dose rhGH on IGF-I levels in obesity and Cushing's syndrome: indirect evaluation of sensitivity to GH. Eur J Endocrinol. 2001; 144(3):251-6. DOI: 10.1530/eje.0.1440251. View

Krassas G, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen J . Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab. 2003; 88(1):132-5. DOI: 10.1210/jc.2002-021349. View

Chen J, Ledet T, Orskov H, Jessen N, Lund S, Whittaker J . A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab. 2003; 284(6):E1149-55. DOI: 10.1152/ajpendo.00410.2002. View

Beck P, KOUMANS J, WINTERLING C, Stein M, Daughaday W, KIPNIS D . STUDIES OF INSULIN AND GROWTH HORMONE SECRETION IN HUMAN OBESITY. J Lab Clin Med. 1964; 64:654-67. View

Frystyk J . Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res. 2004; 14(5):337-75. DOI: 10.1016/j.ghir.2004.06.001. View

10.

Gleeson H, Lissett C, Shalet S . Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. J Clin Endocrinol Metab. 2004; 90(2):1061-7. DOI: 10.1210/jc.2004-0501. View

11.

Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson B, Johannsson G . Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab. 2004; 90(3):1466-74. DOI: 10.1210/jc.2004-1657. View

12.

Schneider H, Saller B, Klotsche J, Marz W, Erwa W, Wittchen H . Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur J Endocrinol. 2006; 154(5):699-706. DOI: 10.1530/eje.1.02131. View

13.

Savastano S, Di Somma C, Belfiore A, Guida B, Orio Jr F, Rota F . Growth hormone status in morbidly obese subjects and correlation with body composition. J Endocrinol Invest. 2006; 29(6):536-43. DOI: 10.1007/BF03344144. View

14.

Conover C, Butler P, Wang M, Rizza R, Lee P . Lack of growth hormone effect on insulin-associated suppression of insulinlike growth factor binding protein 1 in humans. Diabetes. 1990; 39(10):1251-6. DOI: 10.2337/diab.39.10.1251. View

15.

Jorgensen J, Blum W, Moller N, Ranke M, Christiansen J . Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GH-deficient patients. J Clin Endocrinol Metab. 1991; 72(3):582-7. DOI: 10.1210/jcem-72-3-582. View

16.

Cordido F, Casanueva F, Vidal J, Dieguez C . Study of insulin-like growth factor I in human obesity. Horm Res. 1991; 36(5-6):187-91. DOI: 10.1159/000182158. View

17.

Beauregard C, Utz A, Schaub A, Nachtigall L, Biller B, Miller K . Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008; 93(6):2063-71. PMC: 2435650. DOI: 10.1210/jc.2007-2371. View

18.

Brugts M, van den Beld A, Hofland L, van der Wansem K, Van Koetsveld P, Frystyk J . Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. J Clin Endocrinol Metab. 2008; 93(7):2515-22. DOI: 10.1210/jc.2007-1633. View

19.

Utz A, Yamamoto A, Sluss P, Breu J, Miller K . Androgens may mediate a relative preservation of IGF-I levels in overweight and obese women despite reduced growth hormone secretion. J Clin Endocrinol Metab. 2008; 93(10):4033-40. PMC: 2579641. DOI: 10.1210/jc.2008-0930. View

20.

Makimura H, Stanley T, Mun D, You S, Grinspoon S . The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J Clin Endocrinol Metab. 2008; 93(11):4254-60. PMC: 2582562. DOI: 10.1210/jc.2008-1333. View